Eikon Therapeutics, Inc. (EIKN) - What Are Researchers Thinking About This Stock?

Key Points

• Analyst sentiment is moderately positive: Eight firms give Eikon Therapeutics an average “Moderate Buy” rating, with an average 12-month price target of $25.00. Ratings include four buys, one strong buy, one hold and two sells.
• The stock has weakened significantly: EIKN opened at $7.26, near its 12-month low of $7.01 and well below its $17.40 high. The company also reported a quarterly loss of $1.63 per share, slightly worse than analyst expectations.
• Insiders and institutions have shown buying interest: A major shareholder purchased 89,200 shares for about $1.03 million, while several institutional investors—including State Street—established new positions during the second quarter.

Eikon Therapeutics, Inc. (NASDAQ:EIKN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight research firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $25.00.

Several research analysts have weighed in on EIKN shares. Mizuho raised shares of Eikon Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 16th. Weiss Ratings upgraded shares of Eikon Therapeutics from a "sell (e-)" rating to a "sell (e)" rating in a research report on Monday, August 3rd. Wedbush reduced their price target on shares of Eikon Therapeutics from $5.00 to $4.00 and set an "underperform" rating on the stock in a research note on Friday, August 14th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Eikon Therapeutics in a report on Friday, August 21st.

Eikon Therapeutics Trading Down 2.8%

NASDAQ EIKN opened at $7.26 on Tuesday. The stock has a market cap of $393.24 million and a PE ratio of -1.78. Eikon Therapeutics has a twelve month low of $7.01 and a twelve month high of $17.40. The stock has a fifty day simple moving average of $9.59 and a 200-day simple moving average of $10.02.

Eikon Therapeutics (NASDAQ:EIKN - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.61) by ($0.02). Research analysts predict that Eikon Therapeutics will post -7.24 EPS for the current year.

Insider Buying and Selling at Eikon Therapeutics

In related news, major shareholder Group Iv Gp Lp Column bought 89,200 shares of the company's stock in a transaction that occurred on Thursday, September 3rd. The stock was purchased at an average price of $11.56 per share, for a total transaction of $1,031,152.00. Following the acquisition, the insider owned 89,200 shares of the company's stock, valued at approximately $1,031,152. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. State Street Corp purchased a new stake in shares of Eikon Therapeutics in the 2nd quarter valued at $4,621,000. The Manufacturers Life Insurance Company acquired a new position in Eikon Therapeutics during the 2nd quarter worth about $461,000. Integrated Wealth Concepts LLC purchased a new position in Eikon Therapeutics during the 2nd quarter valued at about $142,000. Citadel Advisors LLC purchased a new position in Eikon Therapeutics during the 2nd quarter valued at about $170,000. Finally, Comprehensive Financial Management LLC purchased a new position in Eikon Therapeutics during the 2nd quarter valued at about $1,517,000.

About Eikon Therapeutics

Eikon Therapeutics is a biotechnology company focused on discovering and developing medicines using advanced single-molecule imaging, cell biology and computational technologies. Its platform is designed to track the behavior of proteins and other molecular targets in living cells, with the goal of improving the understanding of disease biology and identifying potential drug candidates.

The company is developing a pipeline of therapeutics, including investigational treatments in areas such as oncology and other serious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.